Make the medicines work around a care home easier to coordinate.

NICE's care-home medicines guidance provides context for safe medicines systems, and NHS England describes person-centred structured medication reviews (NICE, n.d.; NHS England, n.d.). The organisational task should preserve what matters in daily care: practical difficulties, communication needs and questions raised by residents and staff. A list of medicines is not a substitute for that context. The proposed evaluation would examine whether relevant information reaches the responsible reviewer in a usable form, rather than treating a shorter document as proof of a better review.

An appointment can be recorded while questions about documentation, supply or communication remain open. The proposed organisational view would separate the professional review from the actions it generates and the evidence that those actions have been accepted. An administrative closure should never imply that a clinical outcome has occurred. This gives care-home and practice teams a more useful view of work still requiring attention and helps them avoid counting the same task differently in separate organisations' reports.

A coordination view could show reviews awaiting preparation, reviews completed with actions outstanding and episodes whose agreed organisational actions have been closed. Add the effort required from each participating team. Avoid ranking residents by a crude medicines count or presenting administrative closure as clinical success. The useful question is whether the right information and responsibilities move with the work, so the professional review and daily care can be connected without creating another disconnected record.

A bounded PHARMORIS evaluation could compare the existing review-preparation pack with a source-linked organisational brief using synthetic examples and approved process material. Care-home, pharmacy and primary-care reviewers would agree the essential information and handoffs before assessment. The first exercise would not analyse an individual's treatment or change an administration record. It would establish whether the proposed support helps teams organise the task accurately enough to justify considering a later, separately governed operational study.

Stop if a draft loses a resident's relevant concern, confuses an unconfirmed action with a completed one or implies a treatment recommendation outside the agreed scope. Set tolerances for correction burden before testing. If the main difficulty is lack of time for qualified review, the answer may require staffing or service redesign rather than a new preparation tool. The evaluation should make that conclusion possible. Investment is better directed towards the real constraint than towards a polished interface that cannot change it.

A care-home lead, primary-care pharmacist and dispensing pharmacy representative can begin with one recurring coordination problem and a representative example with confidential details removed. We can discuss the comparison and what would make the output useful to each participant. PHARMORIS's proposed role is organisational support within accountable medicines work. It is not a claim of current care-home deployment or proven clinical benefit. A successful evaluation would give the participating organisations a clear reason for the next development step.